ADA 2025 20 - 23 June 2025

Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

Authors :

Nikolaj Bak¹; Rachel Ga Yeon Lee¹; Angela Sinn²; Søren Snitker¹; Valdemar Funch Uhre¹; Emily Wenande¹; Janne R. Hingst¹

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Obesity

Congress poster

GLP-1 RA

CagriSema

PHASE 1 (RCT)

Are you a healthcare professional?